Is BioMarin Pharmaceutical (BMRN) Still Below Fair Value After Its Russell Index Additions?

Simply Wall St.07-08

BioMarin Pharmaceutical (BMRN) was recently added to several Russell indexes, including the Russell 1000 Defensive Index and Russell 2500 Index. This shift could influence how institutional investors ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2649276964?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-07-08 16:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649276964","market":"nz","top_or_hot":-1,"title":"Is BioMarin Pharmaceutical (BMRN) Still Below Fair Value After Its Russell Index Additions?","media":"Simply Wall St.","content":"<div>\n<p>BioMarin Pharmaceutical (BMRN) was recently added to several Russell indexes, including the Russell 1000 Defensive Index and Russell 2500 Index. This shift could influence how institutional investors ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bmrn/biomarin-pharmaceutical/news/is-biomarin-pharmaceutical-bmrn-still-below-fair-value-after\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is BioMarin Pharmaceutical (BMRN) Still Below Fair Value After Its Russell Index Additions?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs BioMarin Pharmaceutical (BMRN) Still Below Fair Value After Its Russell Index Additions?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-08 16:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bmrn/biomarin-pharmaceutical/news/is-biomarin-pharmaceutical-bmrn-still-below-fair-value-after><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioMarin Pharmaceutical (BMRN) was recently added to several Russell indexes, including the Russell 1000 Defensive Index and Russell 2500 Index. This shift could influence how institutional investors ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bmrn/biomarin-pharmaceutical/news/is-biomarin-pharmaceutical-bmrn-still-below-fair-value-after\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BMRN.AU","symbol_name":"Ballymore Resources Ltd","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bmrn/biomarin-pharmaceutical/news/is-biomarin-pharmaceutical-bmrn-still-below-fair-value-after","article_id":"2649276964","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bmrn/biomarin-pharmaceutical/news/is-biomarin-pharmaceutical-bmrn-still-below-fair-value-after","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2649276964","pubTimestamp":1783499382,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BioMarin Pharmaceutical (BMRN) was recently added to several Russell indexes, including the Russell 1000 Defensive Index and Russell 2500 Index. This shift could influence how institutional investors view and access the stock.\nSee our latest analysis for BioMarin Pharmaceutical.\nRecent index additions come alongside a modest pickup in BioMarin Pharmaceutical’s momentum, with a 7 day share price return of 5.47% and a 30 day share price return of 6.31%. However, the 3 year total shareholder...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BMRN.AU":"Ballymore Resources Ltd","BK4139":"生物科技","BMRN":"拜玛林制药","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK7095":"多种金属与采矿","BK4566":"资本集团","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD"},"translate_title":"拜玛林制药(BMRN)在添加罗素指数后是否仍低于公允价值？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMRN":1.5,"BMRN.AU":1.5},"content_text":"BioMarin Pharmaceutical (BMRN) was recently added to several Russell indexes, including the Russell 1000 Defensive Index and Russell 2500 Index. This shift could influence how institutional investors view and access the stock. See our latest analysis for BioMarin Pharmaceutical. Recent index additions come alongside a modest pickup in BioMarin Pharmaceutical’s momentum, with a 7 day share price return of 5.47% and a 30 day share price return of 6.31%. However, the 3 year total shareholder return is still down 29.21%, so recent strength contrasts with weaker long term performance. If this shift in sentiment has you looking beyond BioMarin Pharmaceutical, it could be a time to scan the market for other healthcare and biotech companies applying AI in medicine via the 40 healthcare AI stocks. After a quick rebound and fresh index inclusions, BioMarin Pharmaceutical sits at a crossroads. Is the recent move a sign that most of the easy gains are already behind the stock, or is meaningful upside still ahead on valuation grounds? AdvertisementMost Popular Narrative: 31.3% Undervalued With BioMarin Pharmaceutical last closing at $60.35 against a widely followed fair value estimate of $87.85, the key question is how analysts justify that gap using growth, margins, and risk assumptions.  Strong year-over-year revenue growth driven by increasing global demand, new patient starts, and international expansion of key therapies like VOXZOGO and VIMIZIM aligns with demographic shifts and improved rare disease diagnosis, supporting continued top-line revenue growth.  Read the complete narrative. Curious what kind of revenue runway and margin profile analysts are baking in for BioMarin Pharmaceutical, and how that feeds into a future earnings base and required valuation multiple? The full narrative spells out the growth path, profitability step up, and discount rate that sit behind that $87.85 fair value. Result: Fair Value of $87.85 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the BioMarin Pharmaceutical story could shift quickly if competition in rare disease treatments tightens or if higher R&D and SG&A spending pressures margins and earnings. Find out about the key risks to this BioMarin Pharmaceutical narrative. Another View: BioMarin Pharmaceutical On Earnings Multiples The earlier narrative leans on future cash flows and a fair value of $87.85, yet today BioMarin Pharmaceutical trades on a P/E of 43.4x. That sits above the US Biotechs industry at 17.3x, peers at 33x, and an estimated fair ratio of 27.5x, which raises clear valuation risk questions. For investors who prefer to anchor on what current earnings multiples are implying rather than future cash flow models, the detailed breakdown of this pricing gap is worth a close look, starting with the See what the numbers say about this price — find out in our valuation breakdown.. Here is how BioMarin Pharmaceutical’s valuation stacks up visually against its sector on this basis, which may help you judge whether the premium feels justified or stretched, NasdaqGS:BMRN P/E Ratio as at Jul 2026.Next Steps Given the mixed sentiment around BioMarin Pharmaceutical, it makes sense to review the numbers independently, consider both the potential risks and opportunities, and be ready to act quickly if needed by checking the 2 key rewards and 2 important warning signs. Looking for more investment ideas beyond BioMarin Pharmaceutical? If BioMarin Pharmaceutical has sharpened your focus, do not stop there. Broaden your watchlist with other ideas that fit different risk, income, and quality preferences.  Target potential mispricings by reviewing companies flagged as having better value against fundamentals in the 45 high quality undervalued stocks. Strengthen your income stream by scanning stocks that offer higher yields and consistent payouts through the 9 dividend fortresses. Dial back risk while staying invested by checking companies with steadier balance sheets and metrics in the 74 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if BioMarin Pharmaceutical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649276964","isCrawlerRequest":true}